Loading
Forty Seven developed magrolimab, an antibody that blocks CD47, a signal cancer cells use to stop immune cells from swallowing them. Gilead bought the company in 2020.
Forty Seven, Inc. (formerly Nasdaq: FTSV), of Menlo Park, California, was a clinical-stage immuno-oncology company working on technology licensed from Stanford University. Its lead programme, magrolimab, is a monoclonal antibody against CD47, a 'don't eat me' signal that cancer cells use to avoid being engulfed by macrophages; at the time of sale it was in clinical studies in myelodysplastic syndrome, acute myeloid leukaemia and diffuse large B-cell lymphoma. Gilead agreed on 2 March 2020 to buy Forty Seven for USD 95.50 per share in cash, valuing it at about USD 4.9 billion, and the merger was completed on 7 April 2020.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Gilead's announcement of 2 March 2020, filed as exhibit 99.1 to Forty Seven's 8-K: USD 95.50 per share in cash, approximately USD 4.9 billion | 2020 | $4.9B | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2020-03-02 | Forty Seven to Gilead Sciences (incl. Kite) Magrolimab, anti-CD47 antibody | Acquisition | not disclosed | $4.9bn | source |
The first 'don't eat me' signal blocker. Gilead paid $4.9B for it; it was stopped in 2024 after trials showed more deaths, not fewer.
Shares Magrolimab, CD47, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Magrolimab, CD47, Acute myeloid leukaemia, Diffuse large B-cell lymphoma.
Shares Magrolimab, Gilead Sciences (incl. Kite), Myelodysplastic syndromes / neoplasms (MDS).
Shares Magrolimab, Gilead Sciences (incl. Kite), Acute myeloid leukaemia.
Shares Magrolimab, CD47, Myelodysplastic syndromes / neoplasms (MDS), Monoclonal antibodies.
Shares Magrolimab, Gilead Sciences (incl. Kite), Acute myeloid leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/